Superworth

Silo Pharma PE ratio SILO

Share price divided by earnings per share over the last twelve months, since 2011.

Today, Oct 23, 2026
n/m
losses over the last year
Last meaningful
10.5×
Apr 2022
Earnings per share, 12 months
−$5.41
to Jun 30, 2026
Share price
$1.18
Oct 23, 2026
Peer median
6.1×

Silo Pharma has no meaningful PE ratio today: it lost $5.41 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Apr 2022, at 10.5×.

It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.

Earnings per share over time

A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$9.18n/a
FY2024−$18.00n/a
FY2023−$18.15n/a
FY2022−$20.25−151%
FY2021$39.75n/a
FY2020−$52.50n/a
FY2019−$37.50n/a
FY2018−$15.00n/a
FY2012$0.00n/a
FY2011$0.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.76n/a−$5.41
Q1 FY26−$1.80n/a−$7.53
Q4 FY25−$1.05n/a−$9.18
Q3 FY25−$1.80n/a−$13.98
Q2 FY25−$2.88n/a−$15.48
Q1 FY25−$3.45n/a−$17.25
Q4 FY24−$5.85n/a−$18.00
Q3 FY24−$3.30n/a−$18.00
Q2 FY24−$4.65n/a−$17.85
Q1 FY24−$4.20n/a−$18.00
Q4 FY23−$5.85n/a−$18.15
Q3 FY23−$3.15n/a−$20.25

Against its peers

Companies in Healthcare nearest Silo Pharma's size, closest first, today.

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Silo Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.